标题
Research progress of mTOR inhibitors
作者
关键词
mTOR inhibitor, mTOR, Anticancer, Drug design
出版物
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume 208, Issue -, Pages 112820
出版商
Elsevier BV
发表日期
2020-09-13
DOI
10.1016/j.ejmech.2020.112820
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- RapaLink-1 plays an antithrombotic role in antiphospholipid syndrome by improving autophagy both in vivo and vitro
- (2020) Fangxiang Mu et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Regorafenib and ginsenoside combination therapy: inhibition of HepG2 cell growth through modulating survivin and caspase-3 gene expression
- (2020) B. Wang et al. Clinical & Translational Oncology
- mTOR signaling intervention by Torin1 and XL388 in the insular cortex alleviates neuropathic pain
- (2020) Songyeon Choi et al. NEUROSCIENCE LETTERS
- Effects of mTOR inhibitors on neuropathic pain revealed by optical imaging of the insular cortex in rats
- (2020) Kyeongmin Kim et al. BRAIN RESEARCH
- Potential new therapy of Rapalink‐1, a new generation mammalian target of rapamycin inhibitor, against sunitinib‐resistant renal cell carcinoma
- (2020) Kazuki Kuroshima et al. CANCER SCIENCE
- EGCG protects vascular endothelial cells from oxidative stress-induced damage by targeting the autophagy-dependent PI3K-AKT-mTOR pathway
- (2020) Jiao Meng et al. Annals of Translational Medicine
- mTOR: A Cellular Regulator Interface in Health and Disease
- (2019) Fahd Boutouja et al. Cells
- Correction: Specific blockade of Rictor-mTOR association inhibits mTORC2 activity and is cytotoxic in glioblastoma
- (2019) Angelica Benavides-Serrato et al. PLoS One
- A randomised, placebo-controlled study of omipalisib (PI3K/mTOR) in idiopathic pulmonary fibrosis
- (2019) Pauline T. Lukey et al. EUROPEAN RESPIRATORY JOURNAL
- A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer
- (2019) Hye Joung Choi et al. GYNECOLOGIC ONCOLOGY
- Dual PI3K/mTOR Inhibitor, XL765, suppresses glioblastoma growth by inducing ER stress-dependent apoptosis
- (2019) Hang Zhao et al. OncoTargets and Therapy
- Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma
- (2019) Mi Na Kim et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- The isothiocyanate sulforaphane inhibits mTOR in an NRF2-independent manner
- (2019) Ying Zhang et al. PHYTOMEDICINE
- A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms
- (2019) Edward Wolin et al. PLoS One
- Preclinical Development of PQR514, a Highly Potent PI3K Inhibitor Bearing a Difluoromethyl–Pyrimidine Moiety
- (2019) Chiara Borsari et al. ACS Medicinal Chemistry Letters
- Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway
- (2019) Maria M. Rubinstein et al. CANCER
- Resveratrol: a review of plant sources, synthesis, stability, modification and food application
- (2019) Bingren Tian et al. JOURNAL OF THE SCIENCE OF FOOD AND AGRICULTURE
- Torin2 Exploits Replication and Checkpoint Vulnerabilities to Cause Death of PI3K-Activated Triple-Negative Breast Cancer Cells
- (2019) Sameer S. Chopra et al. Cell Systems
- CC-223 inhibits human head and neck squamous cell carcinoma cell growth
- (2018) Jun-ying Wang et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Inhibition of FOXO1 transcription factor in primary human adipocytes mimics the insulin-resistant state of type 2 diabetes
- (2018) Meenu R. Rajan et al. BIOCHEMICAL JOURNAL
- Cryo-EM structure of human mTOR complex 2
- (2018) Xizi Chen et al. CELL RESEARCH
- New Insights Into the Role of mTOR Signaling in the Cardiovascular System
- (2018) Sebastiano Sciarretta et al. CIRCULATION RESEARCH
- A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer
- (2018) Johanna C. Bendell et al. CLINICAL CANCER RESEARCH
- Autophagy stimulation as a promising approach in treatment of neurodegenerative diseases
- (2018) Karolina Pierzynowska et al. METABOLIC BRAIN DISEASE
- Design, Synthesis, and Docking Studies of New Torin2 Analogs as Potential ATR/mTOR Kinase Inhibitors
- (2018) Althaf Shaik et al. MOLECULES
- Assessment of drug–drug interaction potential and PBPK modeling of CC-223, a potent inhibitor of the mammalian target of rapamycin kinase
- (2018) Zeen Tong et al. XENOBIOTICA
- Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group
- (2018) Martin Fenner et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- An Anti-Cancer Drug Candidate OSI-027 and its Analog as Inhibitors of mTOR: Computational Insights Into the Inhibitory Mechanisms
- (2017) Mohd Rehan JOURNAL OF CELLULAR BIOCHEMISTRY
- 5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology
- (2017) Florent Beaufils et al. JOURNAL OF MEDICINAL CHEMISTRY
- Irinotecan–temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial
- (2017) Rajen Mody et al. LANCET ONCOLOGY
- Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor‐Naïve Advanced Pancreatic Neuroendocrine Tumors
- (2017) Ramon Salazar et al. ONCOLOGIST
- Invitro Evaluation of Torin2 and 2, 6-Dihydroxyacetophenone in Colorectal Cancer Therapy
- (2017) Ankita Awasthi et al. PATHOLOGY & ONCOLOGY RESEARCH
- Sulforaphane inhibits platelet-derived growth factor-induced vascular smooth muscle cell proliferation by targeting mTOR/p70S6kinase signaling independent of Nrf2 activation
- (2017) Noha M. Shawky et al. PHARMACOLOGICAL RESEARCH
- Specific blockade of Rictor-mTOR association inhibits mTORC2 activity and is cytotoxic in glioblastoma
- (2017) Angelica Benavides-Serrato et al. PLoS One
- CC-223 blocks mTORC1/C2 activation and inhibits human hepatocellular carcinoma cells in vitro and in vivo
- (2017) Zichen Xie et al. PLoS One
- Autophagy inhibition sensitizes LY3023414-induced anti-glioma cell activity in vitro and in vivo
- (2017) Lan Zheng et al. Oncotarget
- The preclinical assessment of XL388, a mTOR kinase inhibitor, as a promising anti-renal cell carcinoma agent
- (2017) Zuquan Xiong et al. Oncotarget
- Rapamycin-insensitive companion of mTOR ( RICTOR ) Amplification Defines a Subset of Advanced Gastric Cancer and is Sensitive to AZD2014-mediated mTORC1/2 Inhibition
- (2016) S. T. Kim et al. ANNALS OF ONCOLOGY
- Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma
- (2016) Emmanuel Seront et al. BJU INTERNATIONAL
- A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies
- (2016) Joaquin Mateo et al. BRITISH JOURNAL OF CANCER
- Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors
- (2016) S. O. Dolly et al. CLINICAL CANCER RESEARCH
- A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer
- (2016) Thomas Powles et al. EUROPEAN UROLOGY
- A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer
- (2016) Josep María del Campo et al. GYNECOLOGIC ONCOLOGY
- Temsirolimus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8)
- (2016) Günter Emons et al. GYNECOLOGIC ONCOLOGY
- Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma
- (2016) Jessica L. Geiger et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma
- (2016) Thomas Powles et al. JOURNAL OF CLINICAL ONCOLOGY
- Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study
- (2016) James C. Yao et al. JOURNAL OF CLINICAL ONCOLOGY
- Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study
- (2016) James C Yao et al. LANCET
- Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth
- (2016) M. C. Smith et al. MOLECULAR CANCER THERAPEUTICS
- mTORC2 Puts Its Shoulder to Krebs’ Wheel
- (2016) Sebastian I. Arriola Apelo et al. MOLECULAR CELL
- mTORC2 Responds to Glutamine Catabolite Levels to Modulate the Hexosamine Biosynthesis Enzyme GFAT1
- (2016) Joseph G. Moloughney et al. MOLECULAR CELL
- (−)-Epigallocatechin-3-gallate induces apoptosis in human pancreatic cancer cells via PTEN
- (2016) SHI LIU et al. Molecular Medicine Reports
- An evolutionarily conserved pathway controls proteasome homeostasis
- (2016) Adrien Rousseau et al. NATURE
- Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
- (2016) Vanessa S. Rodrik-Outmezguine et al. NATURE
- Inhibition of mTOR's Catalytic Site by PKI-587 Is a Promising Therapeutic Option for Gastroenteropancreatic Neuroendocrine Tumor Disease
- (2016) Helma Freitag et al. NEUROENDOCRINOLOGY
- A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma
- (2016) Maria I. Carlo et al. ONCOLOGIST
- A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors
- (2016) Oren J. Becher et al. PEDIATRIC BLOOD & CANCER
- Torin2 Suppresses Ionizing Radiation-Induced DNA Damage Repair
- (2016) Durga Udayakumar et al. RADIATION RESEARCH
- mTORC1 induces purine synthesis through control of the mitochondrial tetrahydrofolate cycle
- (2016) I. Ben-Sahra et al. SCIENCE
- Genistein-induced LKB1–AMPK activation inhibits senescence of VSMC through autophagy induction
- (2016) Kyung Young Lee et al. VASCULAR PHARMACOLOGY
- Discovery of Clinical Development Candidate GDC-0084, a Brain Penetrant Inhibitor of PI3K and mTOR
- (2016) Timothy P. Heffron et al. ACS Medicinal Chemistry Letters
- A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors
- (2016) Andrew D.J. Pearson et al. Oncotarget
- RICTOR amplification identifies a subgroup in small cell lung cancer and predicts response to drugs targeting mTOR
- (2016) Nneha Sakre et al. Oncotarget
- Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy
- (2016) Haeseong Park et al. Oncotarget
- The anti-cancer activity of the mTORC1/2 dual inhibitor XL388 in preclinical osteosarcoma models
- (2016) Yun-Rong Zhu et al. Oncotarget
- Sulforaphane inhibits proliferation and invasive activity of everolimus-resistant kidney cancer cells in vitro
- (2016) Eva Juengel et al. Oncotarget
- 4.4 Å Resolution Cryo-EM structure of human mTOR Complex 1
- (2016) Huirong Yang et al. Protein & Cell
- Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study
- (2016) David N. Franz et al. PLoS One
- Toward rapamycin analog (rapalog)-based precision cancer therapy
- (2015) Ling-hua Meng et al. ACTA PHARMACOLOGICA SINICA
- First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014
- (2015) B. Basu et al. CLINICAL CANCER RESEARCH
- Randomized Phase II Trial of Ridaforolimus in Advanced Endometrial Carcinoma
- (2015) Amit M. Oza et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery of Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor CC-223
- (2015) Deborah S. Mortensen et al. JOURNAL OF MEDICINAL CHEMISTRY
- CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization
- (2015) D. S. Mortensen et al. MOLECULAR CANCER THERAPEUTICS
- Unknown
- (2015) Azhar Hussain et al. MOLECULAR MEDICINE
- The novel mTOR inhibitor Torin-2 induces autophagy and downregulates the expression of UHRF1 to suppress hepatocarcinoma cell growth
- (2015) CONGREN WANG et al. ONCOLOGY REPORTS
- Dual PI3K/mTOR inhibitor, XL765 (SAR245409), shows superior effects to sole PI3K [XL147 (SAR245408)] or mTOR [rapamycin] inhibition in prostate cancer cell models
- (2015) Giovanni Luca Gravina et al. TUMOR BIOLOGY
- PtdIns(3,4,5)P3-Dependent Activation of the mTORC2 Kinase Complex
- (2015) P. Liu et al. Cancer Discovery
- Torin2 targets dysregulated pathways in anaplastic thyroid cancer and inhibits tumor growth and metastasis
- (2015) Samira M. Sadowski et al. Oncotarget
- The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells
- (2015) Carolina Simioni et al. Oncotarget
- OSI-027 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine both in vitro and in vivo
- (2015) Xiao Zhi et al. Oncotarget
- A Positive Feedback Loop between Akt and mTORC2 via SIN1 Phosphorylation
- (2015) Guang Yang et al. Cell Reports
- mTORC2 Regulates Cardiac Response to Stress by Inhibiting MST1
- (2015) Sebastiano Sciarretta et al. Cell Reports
- Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation
- (2015) Carolina Simioni et al. Oncotarget
- Synergistic anti-tumor effects of a novel phosphatidyl inositol-3 kinase/mammalian target of rapamycin dual inhibitor BGT226 and gefitinib in non-small cell lung cancer cell lines
- (2014) Yasufumi Katanasaka et al. CANCER LETTERS
- High prevalence of mTOR complex activity can be targeted using Torin2 in papillary thyroid carcinoma
- (2014) Maqbool Ahmed et al. CARCINOGENESIS
- Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer
- (2014) Daliah Tsoref et al. GYNECOLOGIC ONCOLOGY
- Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib
- (2014) Andrew X. Zhu et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Dual PI3K/mTOR Inhibitors, GSK2126458 and PKI-587, Suppress Tumor Progression and Increase Radiosensitivity in Nasopharyngeal Carcinoma
- (2014) T. Liu et al. MOLECULAR CANCER THERAPEUTICS
- Torc1/Torc2 inhibitor, Palomid 529, enhances radiation response modulating CRM1-mediated survivin function and delaying DNA repair in prostate cancer models
- (2014) Giovanni Luca Gravina et al. PROSTATE
- Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial
- (2013) N Colombo et al. BRITISH JOURNAL OF CANCER
- Characterization of Torin2, an ATP-Competitive Inhibitor of mTOR, ATM, and ATR
- (2013) Q. Liu et al. CANCER RESEARCH
- Weekly nab-Rapamycin in Patients with Advanced Nonhematologic Malignancies: Final Results of a Phase I Trial
- (2013) A. M. Gonzalez-Angulo et al. CLINICAL CANCER RESEARCH
- mTORC2 phosphorylates protein kinase Cζ to regulate its stability and activity
- (2013) Xin Li et al. EMBO REPORTS
- Subconjunctival Palomid 529 in the treatment of neovascular age-related macular degeneration
- (2013) Monica Dalal et al. GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
- Dual mTORC1 and mTORC2 inhibitor Palomid 529 penetrates the Blood-Brain Barrier without restriction by ABCB1 and ABCG2
- (2013) Fan Lin et al. INTERNATIONAL JOURNAL OF CANCER
- Ablation of the mTORC2 component rictor in brain or Purkinje cells affects size and neuron morphology
- (2013) Venus Thomanetz et al. JOURNAL OF CELL BIOLOGY
- Results of an International Randomized Phase III Trial of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus Versus Placebo to Control Metastatic Sarcomas in Patients After Benefit From Prior Chemotherapy
- (2013) George D. Demetri et al. JOURNAL OF CLINICAL ONCOLOGY
- Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study
- (2013) Atsushi Ohtsu et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery of a Novel Class of Highly Potent, Selective, ATP-Competitive, and Orally Bioavailable Inhibitors of the Mammalian Target of Rapamycin (mTOR)
- (2013) Craig S. Takeuchi et al. JOURNAL OF MEDICINAL CHEMISTRY
- Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial
- (2013) John J Bissler et al. LANCET
- mTOR kinase structure, mechanism and regulation
- (2013) Haijuan Yang et al. NATURE
- AZD8055 induces cell death associated with autophagy and activation of AMPK in hepatocellular carcinoma
- (2013) MIN HU et al. ONCOLOGY REPORTS
- Torins are potent antimalarials that block replenishment of Plasmodium liver stage parasitophorous vacuole membrane proteins
- (2013) K. K. Hanson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Stimulation of de Novo Pyrimidine Synthesis by Growth Signaling Through mTOR and S6K1
- (2013) I. Ben-Sahra et al. SCIENCE
- Quantitative Phosphoproteomics Reveal mTORC1 Activates de Novo Pyrimidine Synthesis
- (2013) A. M. Robitaille et al. SCIENCE
- Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma
- (2012) A Naing et al. BRITISH JOURNAL OF CANCER
- A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB
- (2012) Carmine Settembre et al. EMBO JOURNAL
- Safety and tolerability of AZD8055 in Japanese patients with advanced solid tumors; a dose-finding phase I study
- (2012) Hajime Asahina et al. INVESTIGATIONAL NEW DRUGS
- VS-5584, a Novel and Highly Selective PI3K/mTOR Kinase Inhibitor for the Treatment of Cancer
- (2012) S. Hart et al. MOLECULAR CANCER THERAPEUTICS
- mTOR Complex 2 Regulates Proper Turnover of Insulin Receptor Substrate-1 via the Ubiquitin Ligase Subunit Fbw8
- (2012) Sung Jin Kim et al. MOLECULAR CELL
- PRR5L degradation promotes mTORC2-mediated PKC-δ phosphorylation and cell migration downstream of Gα12
- (2012) Xiaoqing Gan et al. NATURE CELL BIOLOGY
- Sulforaphane Induces Cell Cycle Arrest and Apoptosis in Acute Lymphoblastic Leukemia Cells
- (2012) Koramit Suppipat et al. PLoS One
- NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity
- (2012) Emmanouil Fokas et al. Radiation Oncology
- Epigallocatechin gallate (EGCG), a major component of green tea, is a dual phosphoinositide-3-kinase/mTOR inhibitor
- (2011) Glenn S. Van Aller et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Identification of 2-oxatriazines as highly potent pan-PI3K/mTOR dual inhibitors
- (2011) Christoph M. Dehnhardt et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Activation of mTORC2 by Association with the Ribosome
- (2011) Vittoria Zinzalla et al. CELL
- mTOR Complex 1 Regulates Lipin 1 Localization to Control the SREBP Pathway
- (2011) Timothy R. Peterson et al. CELL
- Novel Phosphoinositide 3-Kinase/mTOR Dual Inhibitor, NVP-BGT226, Displays Potent Growth-Inhibitory Activity against Human Head and Neck Cancer Cells In Vitro and In Vivo
- (2011) K.-Y. Chang et al. CLINICAL CANCER RESEARCH
- The TORC1/TORC2 inhibitor, Palomid 529, reduces tumor growth and sensitizes to docetaxel and cisplatin in aggressive and hormone-refractory prostate cancer cells
- (2011) G. L. Gravina et al. ENDOCRINE-RELATED CANCER
- Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas
- (2011) Sant P. Chawla et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery of 9-(6-Aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a Potent, Selective, and Orally Available Mammalian Target of Rapamycin (mTOR) Inhibitor for Treatment of Cancer
- (2011) Qingsong Liu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of a Potent, Selective, and Orally Available Class I Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor (GDC-0980) for the Treatment of Cancer
- (2011) Daniel P. Sutherlin et al. JOURNAL OF MEDICINAL CHEMISTRY
- GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway
- (2011) J. J. Wallin et al. MOLECULAR CANCER THERAPEUTICS
- PF-04691502, a Potent and Selective Oral Inhibitor of PI3K and mTOR Kinases with Antitumor Activity
- (2011) J. Yuan et al. MOLECULAR CANCER THERAPEUTICS
- Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin
- (2011) S. V. Bhagwat et al. MOLECULAR CANCER THERAPEUTICS
- AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1
- (2011) Joungmok Kim et al. NATURE CELL BIOLOGY
- Rapamycin passes the torch: a new generation of mTOR inhibitors
- (2011) Don Benjamin et al. NATURE REVIEWS DRUG DISCOVERY
- Everolimus for Advanced Pancreatic Neuroendocrine Tumors
- (2011) James C. Yao et al. NEW ENGLAND JOURNAL OF MEDICINE
- The dual PI3K/mTOR inhibitor NVP-BGT226 induces cell cycle arrest and regulates Survivin gene expression in human pancreatic cancer cell lines
- (2011) Wolfgang Glienke et al. TUMOR BIOLOGY
- Identification of GNE-477, a potent and efficacious dual PI3K/mTOR inhibitor
- (2010) Timothy P. Heffron et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- PKI-179: An orally efficacious dual phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor
- (2010) Aranapakam M. Venkatesan et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- 5-Ureidobenzofuranone indoles as potent and efficacious inhibitors of PI3 kinase-α and mTOR for the treatment of breast cancer
- (2010) Nan Zhang et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Beyond Rapalog Therapy: Preclinical Pharmacology and Antitumor Activity of WYE-125132, an ATP-Competitive and Specific Inhibitor of mTORC1 and mTORC2
- (2010) K. Yu et al. CANCER RESEARCH
- Ragulator-Rag Complex Targets mTORC1 to the Lysosomal Surface and Is Necessary for Its Activation by Amino Acids
- (2010) Yasemin Sancak et al. CELL
- A Ras Signaling Complex Controls the RasC-TORC2 Pathway and Directed Cell Migration
- (2010) Pascale G. Charest et al. DEVELOPMENTAL CELL
- A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF -TRCP
- (2010) B. Zhao et al. GENES & DEVELOPMENT
- Resveratrol Inhibits mTOR Signaling by Promoting the Interaction between mTOR and DEPTOR
- (2010) Meilian Liu et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Randomized, Double-Blind, Placebo-Controlled, Single Intravenous Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the Novel Coronary Smooth Muscle Cell Proliferation Inhibitor Biolimus A9 in Healthy Individuals
- (2010) Wolfgang Steudel et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Discovery of 1-(4-(4-Propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a Highly Potent, Selective Mammalian Target of Rapamycin (mTOR) Inhibitor for the Treatment of Cancer
- (2010) Qingsong Liu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of (Thienopyrimidin-2-yl)aminopyrimidines as Potent, Selective, and Orally Available Pan-PI3-Kinase and Dual Pan-PI3-Kinase/mTOR Inhibitors for the Treatment of Cancer
- (2010) Daniel P. Sutherlin et al. JOURNAL OF MEDICINAL CHEMISTRY
- Bis(morpholino-1,3,5-triazine) Derivatives: Potent Adenosine 5′-Triphosphate Competitive Phosphatidylinositol-3-kinase/Mammalian Target of Rapamycin Inhibitors: Discovery of Compound26(PKI-587), a Highly Efficacious Dual Inhibitor
- (2010) Aranapakam M. Venkatesan et al. JOURNAL OF MEDICINAL CHEMISTRY
- Stereoselective Synthesis of an Active Metabolite of the Potent PI3 Kinase Inhibitor PKI-179
- (2010) Zecheng Chen et al. JOURNAL OF ORGANIC CHEMISTRY
- Dual Inhibition of Akt/Mammalian Target of Rapamycin Pathway byNanoparticle Albumin-Bound–Rapamycin and Perifosine Induces Antitumor Activity in Multiple Myeloma
- (2010) Diana Cirstea et al. MOLECULAR CANCER THERAPEUTICS
- Structure of the Human mTOR Complex I and Its Implications for Rapamycin Inhibition
- (2010) Calvin K. Yip et al. MOLECULAR CELL
- Activation of a Metabolic Gene Regulatory Network Downstream of mTOR Complex 1
- (2010) Katrin Düvel et al. MOLECULAR CELL
- Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis
- (2010) Darcy A. Krueger et al. NEW ENGLAND JOURNAL OF MEDICINE
- FDA Approval Summary: Temsirolimus as Treatment for Advanced Renal Cell Carcinoma
- (2010) V. E. Kwitkowski et al. ONCOLOGIST
- mTOR associates with TFIIIC, is found at tRNA and 5S rRNA genes, and targets their repressor Maf1
- (2010) T. Kantidakis et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin
- (2010) Steven D. Knight et al. ACS Medicinal Chemistry Letters
- Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors
- (2009) J.-C. Soria et al. ANNALS OF ONCOLOGY
- Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)
- (2009) Juan M. García-Martínez et al. BIOCHEMICAL JOURNAL
- Identification and optimisation of novel and selective small molecular weight kinase inhibitors of mTOR
- (2009) Keith A. Menear et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Incorporation of water-solubilizing groups in pyrazolopyrimidine mTOR inhibitors: Discovery of highly potent and selective analogs with improved human microsomal stability
- (2009) David J. Richard et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Discovery of 2-arylthieno[3,2-d]pyrimidines containing 8-oxa-3-azabi-cyclo[3.2.1]octane in the 4-position as potent inhibitors of mTOR with selectivity over PI3K
- (2009) Jeroen C. Verheijen et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- The novel Akt inhibitor Palomid 529 (P529) enhances the effect of radiotherapy in prostate cancer
- (2009) R Diaz et al. BRITISH JOURNAL OF CANCER
- AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity
- (2009) C. M. Chresta et al. CANCER RESEARCH
- Biochemical, Cellular, and In vivo Activity of Novel ATP-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin
- (2009) K. Yu et al. CANCER RESEARCH
- DEPTOR Is an mTOR Inhibitor Frequently Overexpressed in Multiple Myeloma Cells and Required for Their Survival
- (2009) Timothy R. Peterson et al. CELL
- mTOR Mediates Wnt-Induced Epidermal Stem Cell Exhaustion and Aging
- (2009) Rogerio M. Castilho et al. Cell Stem Cell
- Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
- (2009) Georg Hess et al. JOURNAL OF CLINICAL ONCOLOGY
- Lead Optimization of N-3-Substituted 7-Morpholinotriazolopyrimidines as Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitors: Discovery of PKI-402
- (2009) Christoph M. Dehnhardt et al. JOURNAL OF MEDICINAL CHEMISTRY
- Nutrient-dependent mTORC1 Association with the ULK1–Atg13–FIP200 Complex Required for Autophagy
- (2009) Nao Hosokawa et al. MOLECULAR BIOLOGY OF THE CELL
- ULK-Atg13-FIP200 Complexes Mediate mTOR Signaling to the Autophagy Machinery
- (2009) Chang Hwa Jung et al. MOLECULAR BIOLOGY OF THE CELL
- EGCG inhibits protein synthesis, lipogenesis, and cell cycle progression through activation of AMPK in p53 positive and negative human hepatoma cells
- (2009) Chi-Hung Huang et al. MOLECULAR NUTRITION & FOOD RESEARCH
- Inhibitors of phosphoinositide-3-kinase: a structure-based approach to understanding potency and selectivity
- (2009) Teather J. Sundstrom et al. ORGANIC & BIOMOLECULAR CHEMISTRY
- Insulin Stimulates Adipogenesis through the Akt-TSC2-mTORC1 Pathway
- (2009) Hui H. Zhang et al. PLoS One
- Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells
- (2009) Saskia M. Brachmann et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
- (2009) Morris E Feldman et al. PLOS BIOLOGY
- mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1)
- (2008) Juan M. García-Martínez et al. BIOCHEMICAL JOURNAL
- Palomid 529, a Novel Small-Molecule Drug, Is a TORC1/TORC2 Inhibitor That Reduces Tumor Growth, Tumor Angiogenesis, and Vascular Permeability
- (2008) Q. Xue et al. CANCER RESEARCH
- NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations
- (2008) V. Serra et al. CANCER RESEARCH
- SKAR Links Pre-mRNA Splicing to mTOR/S6K1-Mediated Enhanced Translation Efficiency of Spliced mRNAs
- (2008) Xiaoju Max Ma et al. CELL
- SREBP Activity Is Regulated by mTORC1 and Contributes to Akt-Dependent Cell Growth
- (2008) Thomas Porstmann et al. Cell Metabolism
- Adipose-Specific Knockout of raptor Results in Lean Mice with Enhanced Mitochondrial Respiration
- (2008) Pazit Polak et al. Cell Metabolism
- The Identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer†
- (2008) Adrian J. Folkes et al. JOURNAL OF MEDICINAL CHEMISTRY
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
- Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
- (2008) S.-M. Maira et al. MOLECULAR CANCER THERAPEUTICS
- AMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint
- (2008) Dana M. Gwinn et al. MOLECULAR CELL
- Regulation of TORC1 by Rag GTPases in nutrient response
- (2008) Eunjung Kim et al. NATURE CELL BIOLOGY
- Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases
- (2008) Beth Apsel et al. Nature Chemical Biology
- The Rag GTPases Bind Raptor and Mediate Amino Acid Signaling to mTORC1
- (2008) Y. Sancak et al. SCIENCE
- Curcumin as “Curecumin”: From kitchen to clinic
- (2007) Ajay Goel et al. BIOCHEMICAL PHARMACOLOGY
- Targeting phosphoinositide 3-kinase—Moving towards therapy
- (2007) Romina Marone et al. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started